A common complication in the diabetic population

Diabetic Retinopathy is a common disorder affecting 12 million Americans1, which occurs when the blood vessels at the back of the eye (the retina) are damaged .

Early signs of this disease  includes:

  • blurriness
  • “floaters”
  • difficulty perceiving colors
  • dark areas of vision
  • fluctuating vision

This chronic condition is the leading cause of all blindness in the United States, not just those with diabetes2.

%
of diabetics have retinopathy
Diabetic Retinopathy icon

Expensive to manage, making early detection critical

Diabetes-related blindness costs the United States $500 annually3, but through early detection and treatment, the chances of blindness can be reduced by 95%4.
Diagram showing a healthy eye and an eye of a patient with diabetic retinopathy

Diabetic Retinopathy - DRE

DRE is a progressive chronic condition, and the cost of care increases as the disease becomes more severe, making early identification critical to improving patient outcomes and delivering cost-effective care.

There are two main types of DRE. Nonproliferative DRE or early DRE is caused when blood vessels in the retina become damaged, preventing the creation of new blood vessels. Advanced or proliferative DRE is caused when early DRE progresses, leading to the cutoff of blood vessels in the retina, causing new, abnormal blood vessel creation. 

Biomedix Xchange & Diabetic Retinopathy

Biomedix Xchange LogoThe Biomedix Xchange population health management platform enables quick, intuitive, and secure identification of DRE in targeted patient populations. Featuring an integrated technology stack with IRIS, DRE results are automatically aggregated for longitudinal analysis and reporting. This is particularly valuable for polychronic populations managed by value-based care organizations such as Medicare Advantage plans (MAOs), Accountable Care Organizations (ACOs), and Direct Contracting Entities (DCEs).